Justin Xiang, PhD
Chief Investment Officer and Co-Founder
Dr. Xiang is the Chief Investment Officer and Co-Founder of Syno Capital, a global healthcare and biotech investment firm based in New York City that emphasizes on cross-border collaborations between United States and China. In addition, Dr. Xiang is a senior advisor to ZhongAn Insurance, a pioneer online insurance platform in China jointly founded by Alibaba, Tencent and Ping An Insurance, as well as the Chairman and President of ZhongAn Life Sciences, a healthcare solutions subsidiary of ZhongAn Insurance. He advises ZhongAn Insurance on its healthcare strategies and oversee the integration of innovative life sciences with its digital technology and insurance offerings through ZhongAn Life Sciences. Dr. Xiang currently serves as Board Director of several venture-backed companies, including Cynvenio Biosystems, a liquid biopsy diagnostics firm in Los Angeles, CA and Orig3n, a stem cell (iPSC) technology company in Boston, MA. Dr. Xiang is also a member of the International Advisory Council of the Massachusetts General Hospital and advises the hospital on its global initiatives.
Prior to his current roles, Dr. Xiang served as a Senior Scientist at Schrodinger Inc., a software and consulting firm backed by industry leaders including David E. Shaw and Bill Gates that specializes in computer-aided drug design for biopharma companies. He was responsible for developing next- generation computational tools for rational drug design and various other client drug development programs. Previously, Dr. Xiang was also part of Genentech’s Medicinal Chemistry team, where he participated in numerous lead drug candidate optimization projects.
Dr. Xiang holds a doctoral degree in Molecular Biophysics from Washington University Medical School. His research focus was the development of cutting-edge computational models to optimize the drug design process. Dr. Xiang authored several publications on this topic in internationally recognized peer-reviewed journals, including Journal of Computational Chemistry and Journal of Chemical Theory and Computation. He graduated Magna Cum Laude from Washington University in St. Louis with bachelor’s degrees in Biomedical Engineering, Economics, Mathematics and Computer Science.
Joseph Weilgus, CPA
Managing Director and Co-Founder
Mr. Weilgus founded Syno Capital with Dr. Justin Xiang. Mr. Weilgus currently serves as Chief Executive Officer of the RIA, New Legacy Group and their affiliated New Legacy entities. He advises and collaborates on various initiatives with a variety of global industry leaders, entrepreneurs and innovators, celebrities and other successful people.
Prior to founding New Legacy with Adam Geiger in 2007, Mr. Weilgus was President of Geller Holdings, LLC and Managing Director, Client Relations at Geller & Co. In these roles, he advised clients and firm principals on many investments and structured financial transactions, as well as the growth of the company’s business.
Prior to joining Geller, Mr. Weilgus was Director of Client Relations at American Express Tax and Business Services Inc. Before his time with American Express he was a Senior Associate with PricewaterhouseCoopers in the audit practice, where he earned his certified public accountant (CPA) title.
Mr. Weilgus was selected by the Harvard Business School Club of New York as the Not-for-Profit Entrepreneur of the Year in 2002 for his outstanding work as Founder and Chairman of Project Sunshine, a multi-national children’s non-profit organization. Mr. Weilgus founded Project Sunshine out of his college dorm room in 1998. Its 15,000 volunteers now serve over 100,000 children a year in 175 cities across the U.S., Canada, Africa, China and the Middle East. In 2004, he was awarded the 8th Annual Business Leadership Award from Yeshiva University. He, along with Project Sunshine, has received many honors, including ringing the opening and closing bells at the NYSE and NASDAQ exchanges in honor of the Mayor Bloomberg’s declaration of Project Sunshine Week in New York City on several occasions.
Mr. Weilgus earned a B.S. in Accounting from Yeshiva University in 1999 and has participated in executive education programs at Harvard Business School. He was an undefeated NCAA tennis player and Editor-in-Chief of the business newspaper at Yeshiva. He is the Founder and Chairman of the Board of Project Sunshine, an active member of the Young Presidents Organization, and a board member of the American Hebrew Academy in Greensboro, North Carolina.
Hamza joined Syno Capital in 2017. Prior to joining Syno, Hamza was a management consultant at Pathenon-EY, focusing on life sciences growth strategy and transaction due diligence engagements for major pharma, biotech, medical device, and investment companies. He also co-founded SiftWisdom, an enterprise SAAS provider that facilitates healthcare knowledge exchange between industry experts and knowledge seekers.
Hamza graduated from MIT with a B.S. in Chemistry and a minor in Management.
Iris joined Syno Capital in 2017. She is responsible for investor relations, operations, and deals-specific research responsibilities. Previously, she has experience working in investment banking, where she directly supported the Managing Director in capital raising and financial advisory deals for small-cap and mid-cap companies by performing financial analysis and company evaluation to identify investing opportunities. Iris also has experience working for a startup company where she focused on developing marketing strategies and improving performance KPIs for multi-sales platforms.
Iris graduated from Duke University with Master of Management Studies and University of Miami with a BSBA in Marketing and minors in Advertising and Psychology.